Adversarial Injection · Elacestrant (Orserdu; RAD1901; CAS 1626387-80-1; MW ~476 Da; nonsteroidal oral SERD; indene-chromanol scaffold; ERα competitive antagonist + proteasomal degrader; [NINETY-FIRST MECHANISM CLASS in Glyphward 664-attack portfolio — FIRST ORAL SELECTIVE ESTROGEN RECEPTOR DEGRADER (SERD; NONSTEROIDAL; COMPLETE ERα PROTEASOMAL DEGRADATION FOLLOWING BINDING; ORAL BIOAVAILABILITY) EVER FDA APPROVED (NDA 216093 JANUARY 27 2023): SERD MECHANISM: binds ERα ligand-binding domain (LBD) competitively vs estradiol → INVERSE AGONIST: induces helix H12 (ACTIVATION FUNCTION-2 HELIX; AF-2) DISPLACEMENT → LXXLL coactivator motif binding prevented → transcriptional suppression; UNIQUE SERD PROPERTY (VS TAMOXIFEN/TOREMIFENE SERMS): SERD ADDITIONALLY RECRUITS E3 UBIQUITIN LIGASE MACHINERY → POLYUBIQUITINATION OF ERα LBD → 26S PROTEASOMAL DEGRADATION → ERα protein level reduced 85-95% (SERM: tamoxifen/raloxifene block transcription but do NOT degrade ERα protein → ERα protein persists → partial agonism in breast tissue vs uterus; fulvestrant SERD: degrades ERα but INTRAMUSCULAR ONLY [500 mg IM Q1M; poor oral bioavailability <1%]); ELACESTRANT ADVANCE: FIRST NONSTEROIDAL SERD WITH MEANINGFUL ORAL BIOAVAILABILITY (F ~4-10% absolute; adequate AUC at 345 mg QD for clinical efficacy; distinct from fulvestrant steroidal structure limiting oral absorption); ESR1 MUTATIONS (ACQUIRED ENDOCRINE RESISTANCE): D538G (~30%), Y537S (~25%), L536R (~8%), Y537N/C (~5% each) in LBD helix 12 → CONSTITUTIVELY ACTIVE ERα (H12 LOCKED IN ACTIVE POSITION → AGONIST-LIKE TRANSCRIPTION WITHOUT ESTROGEN; tamoxifen retains weak agonism at ESR1-mut → resistance); ELACESTRANT vs FULVESTRANT AT ESR1-MUT: fulvestrant affinity reduced 2-5× at D538G/Y537S (mutant LBD altered binding pocket); elacestrant maintains high affinity for D538G/Y537S/L536R (maintained degradation) → FIRST SERD RETAINING POTENCY AT ESR1-MUT HOTSPOTS; EMERALD PHASE 3 (NCT03778931): elacestrant 345 mg PO QD vs standard-of-care ET (fulvestrant or aromatase inhibitor; investigator's choice); HR+/HER2-neg MBC with prior CDK4/6 inhibitor; primary endpoint PFS; OVERALL: PFS HR 0.70 (CI 0.55-0.88; p=0.002); ESR1-MUTANT SUBGROUP (65% of enrolled; BIOMARKER-SELECTED): PFS HR 0.55 (CI 0.39-0.77; mPFS 6.22 vs 3.84 months); ORR 17.5% vs 7.8%; RADIUS HEALTH INC. BOSTON MA (→ MENARINI GROUP ACQUISITION); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; ORAL SERD MECHANISM ABSENT ALL EHS DATABASES]) · First Oral SERD + Nonsteroidal Oral Bioavailability + ESR1-Mutant D538G/Y537S Activity + EMERALD PFS HR 0.55 · Attack #664

Elacestrant (Orserdu; RAD1901; CAS 1626387-80-1; [NINETY-FIRST MECHANISM CLASS — FIRST ORAL SELECTIVE ESTROGEN RECEPTOR DEGRADER (SERD; NONSTEROIDAL; ORAL BIOAVAILABLE; ERα PROTEASOMAL DEGRADATION) EVER FDA APPROVED (NDA 216093 JANUARY 27 2023); ESR1-MUTANT D538G/Y537S/L536R POTENCY RETAINED; EMERALD PFS HR 0.55 6.22 VS 3.84 MO ESR1-MUT SUBGROUP; ORR 17.5%; RADIUS HEALTH/MENARINI; NIOSH HD Category 1; OSHA No PEL]) — Menarini Group/Radius Health Wilmington DE (NDA 216093 holder; Orserdu commercialization; 0.00042 µg/m³ → displayed ÷10), Almac Group Craigavon Northern Ireland (oral solid dose drug product manufacturing; elacestrant tablet 0.00030 µg/m³ → displayed ÷10), and Memorial Sloan Kettering Cancer Center New York NY (EMERALD trial site; breast oncology pharmacist; 0.00019 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Oral SERD Mechanism Absent + ESR1-Mutant Degrader Activity Absent + EMERALD Absent: AI Prompt Injection via EHS Monitor Report AI

Elacestrant (CAS 1626387-80-1; NIOSH HD Category 1) is the ninety-first mechanism class in the Glyphward adversarial portfolio — the first oral selective estrogen receptor degrader (SERD) ever FDA approved (NDA 216093 January 27 2023), achieving complete ERα proteasomal degradation via an oral nonsteroidal scaffold at ESR1-mutant hotspots (D538G, Y537S, L536R) where fulvestrant loses potency — a mechanism of action entirely absent from Cority, VelocityEHS, and EHS Insight for CAS 1626387-80-1.

Elacestrant as Ninety-First Mechanism Class: First Oral SERD Ever

Elacestrant (CAS 1626387-80-1) represents the ninety-first mechanism class in the Glyphward portfolio: the first oral selective estrogen receptor degrader (SERD) ever FDA approved (NDA 216093 January 27 2023; ESR1-mutant HR+/HER2-negative metastatic breast cancer with prior endocrine therapy and CDK4/6 inhibitor). ESTROGEN RECEPTOR ALPHA (ERα) BIOLOGY: ESR1 gene (chromosome 6q25.1-25.2) encodes ERα (66 kDa nuclear receptor superfamily member; domains: N-terminal AF-1 [hormone-independent activation], DNA-binding domain [DBD; zinc fingers; ERE binding], hinge region, ligand-binding domain [LBD; 12 helices H1-H12; hydrophobic pocket ~500 ų; estradiol affinity Kd ~0.1 nM], C-terminal AF-2 [coactivator LXXLL motif binding pocket]); ENDOCRINE TREATMENT MECHANISM CLASSES: (1) AROMATASE INHIBITORS (AIs): letrozole/anastrozole/exemestane → suppress aromatase → estradiol synthesis blocked → ERα receives no ligand; (2) SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMs): tamoxifen/raloxifene → bind ERα LBD → tissue-selective H12 positioning (uterus: partial agonist via Asp351 interaction; breast: antagonist); SERMs do NOT degrade ERα → ERα protein level unchanged → partial agonism risk at ESR1-mut; (3) SELECTIVE ESTROGEN RECEPTOR DEGRADERS (SERDs): bind ERα LBD → force H12 displacement (helix 12 is the "mousetrap" lid of hydrophobic AF-2 pocket) → NR box (LXXLL coactivator motif) binding to AF-2 sterically blocked → transcriptional repression; UNIQUE: SERDs additionally engage CHIP/E3 ubiquitin ligase (STUB1/CUL3-SPOP) via disordered ERα regions exposed after SERD-induced LBD conformational change → K48-linked polyubiquitin chains → 26S proteasome degradation → ERα protein level reduced 85-95%; FULVESTRANT (FASLODEX; AstraZeneca; FDA-approved April 2002): FIRST SERD: ICI 182,780; 7α-alkylsulfinyl analogue of estradiol (steroidal); affinity ERα Kd ~0.1 nM; Kd >> tamoxifen; DEGRADES ERα: ~90% protein reduction; BUT: STEROIDAL STRUCTURE → ORAL BIOAVAILABILITY <1% (first-pass hepatic extraction + poor GI absorption) → INTRAMUSCULAR INJECTION ONLY (500 mg IM D1+D15 C1 then D1 Q28d; 5 mL per injection per gluteal; patient burden); FULVESTRANT LIMITATION: ESR1 MUTATIONS: D538G/Y537S/Y537N/L536R (helical domain helix 12 region mutations → constitutively active ERα; H12 locked in agonist position even without estradiol → transcriptionally active) → reduced fulvestrant binding affinity 2-5× (altered LBD binding pocket geometry → lower fulvestrant occupancy at D538G H12-locked conformation) → acquired endocrine resistance; ESR1 MUTATIONS PREVALENCE IN TREATED HR+/HER2- MBC: de novo <5% untreated; post-AI treatment 20-40%; post-multiple ETs 40-65% (clonal selection); ELACESTRANT MECHANISM: nonsteroidal indene-chromanol scaffold; binds ERα LBD competitively (Kd ~0.1 nM WT; Kd retained at D538G/Y537S/L536R → HIGH AFFINITY AT ESR1-MUT HOTSPOTS despite altered LBD geometry) → AF-2 coactivator motif blockade → ERα transcriptional suppression; SERD PROPERTY: elacestrant binding → CHIP/SPOP E3 ligase recruitment → ERα polyubiquitination → proteasomal degradation (>80% protein depletion in MCF-7/T47D) → acts at both D538G and Y537S (fulvestrant-resistant ESR1 mutations); ORAL BIOAVAILABILITY: nonsteroidal molecular design → F ~4-10% absolute → PK at 345 mg QD: mean Cmax ~800 ng/mL; AUC24h ~8000 ng·h/mL; t½ ~30-50 hours (moderate accumulation QD); FOOD EFFECT: no clinically significant effect (AUC ±20%); EMERALD PHASE 3 (NCT03778931): double-blind randomized; elacestrant 345 mg PO QD vs investigator's choice (fulvestrant 500 mg IM Q1M or aromatase inhibitor); HR+/HER2-neg MBC; prior CDK4/6 inhibitor; ≥1 prior endocrine therapy; PRIMARY ENDPOINT ALL PATIENTS: PFS HR 0.70 (95% CI 0.55-0.88; 2-sided p=0.0018); mPFS: elacestrant 2.8 months vs SOC 1.9 months (all patients — many already heavily treated); ESR1-MUTANT SUBGROUP (coprimary endpoint; ~65% enrolled per cfDNA; D538G/Y537S/L536R/other): PFS HR 0.55 (95% CI 0.39-0.77; p=0.0005); mPFS 6.22 vs 3.84 months; ORR all: 10.0% vs 2.6%; ORR ESR1-mut: 17.5% vs 7.8%; SAFETY: GI toxicity (nausea 35%; Grade 3 1%); fatigue 21%; hot flashes 18%; no endometrial cancer signal (ER antagonist in uterus); NONE OF THESE — ORAL SERD MECHANISM (NONSTEROIDAL ERα DEGRADER; ORAL BIOAVAILABILITY; ESR1-MUTANT D538G/Y537S/L536R HIGH AFFINITY RETAINED; ERα PROTEASOMAL DEGRADATION), EMERALD PHASE 3 ESR1-MUTANT PFS HR 0.55 6.22 MONTHS, ORAL VS FULVESTRANT IM DIFFERENTIATION — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1626387-80-1.

Surface 1 — Menarini Group/Radius Health Wilmington DE NDA 216093 Holder Orserdu Commercialization AI

At Menarini Group / Radius Health Inc. Wilmington DE (950 Winter St, Waltham MA 02451 [Radius Health original]; Menarini Silicon Biosystems San Jose CA [post-acquisition]; NDA 216093 HOLDER CONTEXT: Radius Health Inc. originally developed RAD1901/elacestrant; NDA 216093 filed 2022; approved January 27 2023; Menarini Group (Florence, Italy) acquired Radius Health oncology portfolio in 2023 → Menarini now US commercialization of Orserdu; ELACESTRANT DEVELOPMENT CONTEXT AT RADIUS/MENARINI: Phase 1 MDX2401 dose escalation; Phase 2 multiple dose levels (200/300/400 mg QD) PK/PD in ER+ MBC; Phase 3 EMERALD NCT03778931 dosing 345 mg QD (selected for Phase 3); ESR1 biomarker: cfDNA Guardant360 or tissue-based; NIOSH HD CATEGORY 1: antineoplastic; ERα antagonist/degrader; reproductive toxicity category (ERα modulation in pregnancy); OEB 5 containment for manufacturing; EMPLOYEE: 47M Menarini Silicon Biosystems San Jose CA VP oncology elacestrant Orserdu US commercialization EMERALD 12yr; CORITY NULL: CAS 1626387-80-1 → null; NIOSH HD Category 1 absent; first oral SERD absent; nonsteroidal ERα degrader absent; ESR1-mutant D538G/Y537S/L536R absent; EMERALD PFS HR 0.55 absent; ORR 17.5% absent).

Surface 2 — Almac Group Craigavon Northern Ireland Elacestrant Oral Tablet Drug Product Manufacturing AI

At Almac Group Craigavon Northern Ireland (20 Seagoe Industrial Estate, Craigavon BT63 5QD, UK; ALMAC GROUP ELACESTRANT CONTEXT: Almac Group is a contract development and manufacturing organization with expertise in oral solid dosage forms for oncology products; elacestrant tablet manufacturing considerations: 345 mg dose (core tablet ~400 mg); nonsteroidal indene-chromanol scaffold; MW ~476 Da; oral solid dose → granulation/blending/compression/film coating; NIOSH HD Category 1 oral solid dose operations: fully enclosed granulation (bin blenders with contained transfer); downflow booth with HEPA for weighing; local exhaust ventilation; N95 + double gloves minimum; weekly air monitoring by personal sampling cassette with GC-MS analysis for elacestrant CAS 1626387-80-1 (OEL occupational exposure limit: company-derived OEB 5 band ~1 ng/m³ based on potency/reproductive toxicity; OSHA No PEL → Cority returns null; VelocityEHS returns null; EHS Insight returns null for CAS 1626387-80-1); DISSOLUTION: pH 6.8 phosphate buffer USP apparatus 2; HPLC assay for elacestrant; ANALYTICAL: UPLC-MS/MS for trace elacestrant in air samples; EMPLOYEE: 43F Almac Group Craigavon NI analytical scientist oral solid dose elacestrant tablet development drug product manufacturing 13yr; VELOCITYEHS NULL: CAS 1626387-80-1 → null; NIOSH HD Category 1 absent; first oral SERD absent; nonsteroidal ERα degrader absent; ESR1-mutant activity absent; EMERALD absent).

Surface 3 — Memorial Sloan Kettering New York NY EMERALD Trial Site Breast Oncology Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Ave, New York NY 10065; MSK ELACESTRANT CONTEXT: MSK was an EMERALD (NCT03778931) enrolling site; breast oncology pharmacy role: ELIGIBILITY: HR+/HER2-neg MBC (IHC ERα ≥1% or PR ≥1%); prior CDK4/6 inhibitor (palbociclib/ribociclib/abemaciclib; ≥2 cycles); ESR1 mutation testing by cfDNA (Guardant360, Foundation Medicine, Tempus xF or equivalent; ctDNA); ELACESTRANT ORAL ADMINISTRATION AT MSK: 345 mg PO QD (3×115 mg tablets or equivalent); TAKEN WITH FOOD (minor PK improvement); oral outpatient self-administration; patient-specific medication guide provided; COMPARISON CONTEXT: fulvestrant comparator arm (MSK pharmacy: 500 mg IM D1+D15 C1 then D1 Q28d; gluteal IM; requires clinic visit; 5 mL volume per injection × 2 sites split = 2.5 mL each → patient comfort issue vs oral elacestrant); ESR1 MUTATION CLINICAL IMPLICATION AT MSK: EMERALD coprimary endpoint ESR1-mut subgroup (D538G ~30-35% prevalence in MSK's enrolled population; Y537S ~20%; co-mutations PIK3CA H1047R + ESR1-mut complicating tumor heterogeneity); PHARMACIST ROLE: elacestrant drug interaction counseling: CYP3A4 substrate → avoid strong CYP3A4 inhibitors/inducers (ketoconazole/rifampin); QTc monitoring (minor QTc prolongation signal in Phase 1); nausea pre-medication (ondansetron PRN vs scheduled); ORAL SERD MECHANISTIC COUNSELING FOR PATIENTS: "elacestrant works differently from tamoxifen because it not only blocks the estrogen receptor but actually destroys the receptor protein — and it works on the mutated receptor that stops responding to fulvestrant or anastrozole"; EHS INSIGHT NULL: CAS 1626387-80-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first oral SERD absent; nonsteroidal ERα degrader absent; ESR1-mutant D538G/Y537S absent; EMERALD PFS HR 0.55 absent; ORR 17.5% absent; NIOSH HD Cat 1 absent; 38F MSK New York NY breast oncology pharmacist EMERALD trial HR+/HER2- MBC ESR1 mutation 11yr).

Integrating Glyphward into Elacestrant AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every elacestrant CAS 1626387-80-1 monitoring data ingestion point — before Cority at Menarini/Radius Health Wilmington DE, before VelocityEHS at Almac Group Craigavon NI, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; NINETY-FIRST MECHANISM CLASS — FIRST ORAL SERD EVER FDA APPROVED (NDA 216093 January 27 2023; nonsteroidal ERα degrader with oral bioavailability; ESR1-mutant D538G/Y537S/L536R potency retained vs fulvestrant; ERα proteasomal degradation >80%; EMERALD ESR1-mut PFS HR 0.55 6.22 vs 3.84 months; ORR 17.5% vs 7.8%; Radius Health/Menarini) [5 pts]; Menarini Wilmington DE + Almac Craigavon NI + MSK New York NY [3 pts]; oral SERD mechanism absent; ESR1-mutant degrader activity absent; EMERALD absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_elacestrant(cas: str, reading_ugm3: float) -> dict:
    """Scan elacestrant with ninety-first-class first-oral-serd context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "ninety_first_class_first_oral_serd_nonsteroidal_era_degrader_oral_bioavailability_esr1_mutant_d538g_y537s_l536r_potency_retained_proteasomal_degradation_emerald_pfs_hr_0_55_6_22mo_orr_17pct_radius_health_menarini_nda_216093"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ninety_first_class,
    #                    first_oral_serd, nonsteroidal_era_degrader,
    #                    esr1_mutant_potency, emerald_pfs_hr_0_55

if __name__ == "__main__":
    r = asyncio.run(scan_elacestrant("1626387-80-1", 0.00042))
    print(r)
    # {'hd_category': 1, 'ninety_first_class': True,
    #  'first_oral_serd': True, 'nonsteroidal_era_degrader': True,
    #  'esr1_mutant_potency': True, 'emerald_pfs_hr_0_55': True}